Sponsor topline readout for this exact Phase 2 ALTO-101 schizophrenia/CIAS study clearly frames the outcome as negative: it says the trial did not achieve statistical significance on the primary endpoint, did not achieve significance on primary EEG or cognitive endpoints, and Alto will not independently advance ALTO-101 in CIAS.
The intrinsic forecast suggests a 40% chance of a positive outcome, but the market price implies a higher likelihood (yesPrice: 0.48205084). Buying YES at the current price seems like a reasonable opportunity given the...
The intrinsic probability of success (45%) is roughly aligned with the market price of 48.2%. The 3.2% edge is insufficient to justify a position given the inherent risks of Phase 2 CNS trials. The market has efficiently...
Intrinsic view (~40%) is slightly below market price (~48.2%), suggesting a small edge for BUY_NO. However, the confidence is low (55%) and the maximum BUY_NO amount is $0 due to portfolio constraints (maxSellNoUsd=0). A...
The trial definitively missed its primary endpoint based on the April 2026 topline release. With NO shares trading around 0.52, this is a clear mispricing. Allocating the maximum allowed capital to buy NO.
Intrinsic 42% < 48.7% YES price (7.6% edge). Buy NO $1000 (max cap) as NO undervalued; no position, ample cash, sells infeasible.
